loader image
Aquila Path Technology

Understanding more from every biopsy

The Aquila Path Foundation Model interprets digitized prostate H&E alongside relevant clinical context. APFM powers TruGrade™, an objective biological risk assessment designed to complement conventional pathology and support physician-led interpretation.

The Aquila Path Foundation Model

A foundation model built around prostate pathology

Developed specifically for prostate pathology, the Aquila Path Foundation Model - APFM analyzes patterns within routine tissue and connects them to relevant clinical evidence. The resulting tissue intelligence forms the foundation of the TruGrade™ biological risk assessment.

Tissue Evidence
Illustrative digitized prostate H&E tissue

Routine digitized pathology provides the biological foundation.

APFM

Aquila Path
Foundation Model

Multimodal tissue and clinical intelligence.

Clinical Context

Selected patient information can add clinically relevant perspective.

TruGrade™ Score Objective Biological Risk Assessment

01

Foundation-Scale Learning

Learns broad tissue representations from prostate pathology and associated clinical evidence.

02

Multimodal Context

Interprets complementary categories of evidence together rather than viewing tissue and clinical context in isolation.

03

One Interpretable Output

Translates multidimensional information into a biological risk assessment intended to complement conventional pathology.

The TruGrade™ Score

One score. Greater biological context.

TruGrade™ brings multidimensional tissue evidence and relevant clinical context into a single interpretable assessment of biological risk. Presented along a continuous scale, it is designed to complement conventional pathology and support physician-led evaluation.

Technology Principles

Built on biology. 
Grounded in outcomes.

APFM is developed around the biological and clinical purpose of the assessment with a focused approach to prostate tissue intelligence.

Biology First

Centered on clinically meaningful tissue morphology, gland architecture, spatial relationships, and prostate disease biology.

Quantitative by Design

Computational analysis supports a structured and more consistent interpretation of tissue evidence across patient cases.

Outcome Grounded

The Aquila Path Foundation Model is formed by longitudinal clinical evidence and relevant endpoints that indicate how the disease may progress overtime.

Built for Discovery

Designed to support research into emerging biological relationships and potential tissue-based biomarkers within prostate pathology.

PURPOSE BUILT FOCUS

Designed for prostate tissue intelligence

APFM is developed specifically around prostate biopsy tissue, disease biology and the clinical context relevant to biological-risk interpretation.

  • Specimen context preserved
  • Patient context considered
  • Physician-led interpretation
Clinical Workflow

Designed for practical clinical integration

A clear three-stage path from digitized routine pathology to an interpretable TruGrade™ report with implementation tailored to the laboratory and clinical environment.

01 Digital Pathology Intake

Digital Pathology Intake

Digitized routine H&E images enter the workflow through processes aligned with participating laboratory systems and requirements.

02 Aquila Path Analysis

Aquila Path Analysis

APFM evaluates tissue morphology, spatial organization, and the relevant clinical context of each patient’s individual case.

03 TruGrade™ Report

TruGrade™ Report

A structured report presents an objective biological risk assessment for consideration alongside conventional pathology to support physician-led interpretation.

Bring deeper tissue intelligence into clinical practice

Q

What would you like to explore with us?